Moomoo AI 已提取核心訊息
On March 7, 2024, C4 Therapeutics, Inc. announced the repricing of certain stock options under its 2020 Stock Option and Incentive Plan. The Organization, Leadership and Compensation Committee of the company's Board of Directors approved the repricing, which is applicable to options with an exercise price above $22.00. The repriced options include those held by several executive officers but exclude options held by the President and CEO, Andrew Hirsch, and non-employee Board members. For senior leadership, the new exercise price is set at $19.00 per share, the company's IPO price, while for other employees, it is $11.88, the 52-week high. The repriced options will revert to their original price if the holder leaves the company or exercises the options within a year from the Effective Date. This move aims to retain and motivate employees without significant stock dilution or additional cash compensation.
On March 7, 2024, C4 Therapeutics, Inc. announced the repricing of certain stock options under its 2020 Stock Option and Incentive Plan. The Organization, Leadership and Compensation Committee of the company's Board of Directors approved the repricing, which is applicable to options with an exercise price above $22.00. The repriced options include those held by several executive officers but exclude options held by the President and CEO, Andrew Hirsch, and non-employee Board members. For senior leadership, the new exercise price is set at $19.00 per share, the company's IPO price, while for other employees, it is $11.88, the 52-week high. The repriced options will revert to their original price if the holder leaves the company or exercises the options within a year from the Effective Date. This move aims to retain and motivate employees without significant stock dilution or additional cash compensation.
2024年3月7日，C4 Therapeutics, Inc.宣佈根據其2020年股票期權和激勵計劃對某些股票期權進行重新定價。公司董事會的組織、領導和薪酬委員會批准了重新定價，適用於行使價高於22.00美元的期權。重新定價的期權包括幾位執行官持有的期權，但不包括總裁兼首席執行官安德魯·赫希和非僱員董事會成員持有的期權。對於高級領導層而言，新的行使價定爲每股19.00美元，即公司的IPO價格，而其他員工的行使價爲11.88美元，爲52周的最高水平。如果持有人在生效日期後的一年內離開公司或行使期權，則重新定價的期權將恢復到其原始價格。此舉旨在在不大幅稀釋股票或額外現金補償的情況下留住和激勵員工。
2024年3月7日，C4 Therapeutics, Inc.宣佈根據其2020年股票期權和激勵計劃對某些股票期權進行重新定價。公司董事會的組織、領導和薪酬委員會批准了重新定價，適用於行使價高於22.00美元的期權。重新定價的期權包括幾位執行官持有的期權，但不包括總裁兼首席執行官安德魯·赫希和非僱員董事會成員持有的期權。對於高級領導層而言，新的行使價定爲每股19.00美元，即公司的IPO價格，而其他員工的行使價爲11.88美元，爲52周的最高水平。如果持有人在生效日期後的一年內離開公司或行使期權，則重新定價的期權將恢復到其原始價格。此舉旨在在不大幅稀釋股票或額外現金補償的情況下留住和激勵員工。
有用
沒用